Last checked at 20 Jan 2022 10:50
20 January 2022
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the AI digital technologies company serving neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
RESOLUTION | VOTESFOR | % | VOTESAGAINST | % | VOTESTOTAL | % ISC VOTED | VOTESWITHHELD | |
1 | Reports and Accounts
| 30,181,599 | 99.99 | 800 | 0.01 | 30,184,099 | 62.69 | 1,700 |
2a | Re-election of Charles Spicer
| 30,166,631 | 99.97 | 10,107 | 0.03 | 30,184,099 | 62.69 | 7,361 |
2b | Re-election of Grant Nash | 30,166,931 | 99.97 | 9,807 | 0.03 | 30,184,099 | 62.69 | 7,361 |
3 | Re-appointment of Auditors
| 29,764,948 | 98.66 | 405,081 | 1.34 | 30,184,099 | 62.69 | 14,070 |
4 | Allotment of Securities
| 30,172,562 | 99.97 | 10,037 | 0.03 | 30,184,099 | 62.69 | 1,500 |
5 | * Disapply Pre-Emption Provisions | 30,149,112 | 99.89 | 33,487 | 0.11 | 30,184,099 | 62.69 | 1,500 |
* Special Resolution
Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer | ||||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) | ||||
Michael F Johnson (Sales) | ||||
Walbrook PR Ltd | +44 (0)20 7933 8780 | |||
Paul McManus / Lianne Applegarth / | IXICO@walbrookpr.com | |||
Alice Woodings
| ||||
| ||||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc